SinoMab BioScience Limited (HKG:3681)
Hong Kong · Delayed Price · Currency is HKD 1.760
-0.010 (-0.56%)
At close: Mar 27, 2026
SinoMab BioScience Revenue
SinoMab BioScience had revenue of -9.78M CNY in the half year ending December 31, 2025.
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
61
Market Cap
2.44B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 2.03M | 661.00K | 48.42% |
| Dec 31, 2023 | 1.37M | -2.67M | -66.15% |
| Dec 31, 2022 | 4.03M | -22.63M | -84.87% |
| Dec 31, 2021 | 26.66M | 13.90M | 108.91% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Frontage Holdings | 1.99B |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.43B |
| AIM Vaccine | 1.38B |
| Mabpharm | 718.98M |
| Medtide | 546.29M |
| Cutia Therapeutics | 374.07M |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 171.70M |
| Antengene Corporation | 117.22M |